TABLE 1.

Percent relative changes in bioluminescence for critical concentrations of the antimicrobial agents tested

Antibiotic type and antibiotic	Concn (μg/ml)	Relative change in biolumines-cence (%) on the following daya:
		3	7	14
Cell wall biosynthesis inhibitors
d-Cycloserine	12.5	32.1 ± 3.5	28.9 ± 2.8	9.2 ± 1.5
	25bc	2.3 ± 0.5	0.4 ± 0.1	<0.2
	50	<0.2	<0.2	<0.2
Ethambutol	5	55 ± 10	24 ± 22	25.1 ± 5.8
	10c	18.4 ± 3.9	2.2 ± 0.5	<0.2
	20b	7.9 ± 1.9	1.1 ± 0.4	<0.2
	40	5.8 ± 1.4	1.4 ± 0.4	<0.2
Isoniazid	62.5	63 ± 17	163 ± 49	97 ± 27
	125	38 ± 10	93 ± 25	86 ± 22
	250	11.3 ± 2.9	11.5 ± 3.1	53 ± 13
DNA supercoiling inhib-itors, Bay y 3118	0.0	100 ± 19	100 ± 20	100 ± 19
	0.008c	39 ± 42	4.5 ± 5.7	0.7 ± 0.8
	0.015b	24.2 ± 4.6	1.4 ± 0.6	0.5 ± 0.4
	0.03	13.5 ± 2.8	0.7 ± 0.6	<0.2
Protein biosynthesis inhibitors
Aminoglycosides
Amikacin	1	86.3 ± 5.3	126 ± 14	95 ± 11
	2c	52.0 ± 8.0	65 ± 11	0.4 ± 0.3
	4	15.4 ± 1.4	8.1 ± 0.9	0.6 ± 0.9
	8	7.2 ± 1.3	1.9 ± 0.3	0.2 ± 0.2
	16b	3.0 ± 1.3	0.5 ± 0.1	0.2 ± 0.1
Kanamycin	32	91 ± 32	91 ± 31	429 ± 150
	64	83 ± 29	99 ± 34	453 ± 151
	128	56 ± 19	68 ± 25	220 ± 100
Macrolide, clarithro-mycin	0.625	34.7 ± 7.2	68 ± 23	18.3 ± 3.2
	1.25bc	5.2 ± 3.8	1.1 ± 2.0	0.2 ± 0.3
	2.5	6.1 ± 1.8	0.4 ± 0.3	<0.2
Transcription inhibitors
Rifabutin	0.25	8.5 ± 2.7	11.7 ± 2.6	30.7 ± 6.7
	0.5bc	6.0 ± 1.6	0.5 ± 0.3	0.2 ± 0.2
	1	5.1 ± 1.6	0.2 ± 0.1	<0.2

^aBoldface type indicates a relative change in luminescence of ≤1.0% + 0.5%. 

^bMIC for day 7. 

^cMIC for day 14.